FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023598302> ?p ?o ?g. }

• W2023598302 endingPage "S184" @default.
• W2023598302 startingPage "S181" @default.
• W2023598302 abstract "The core loss of dopaminergic neurons in the substantia nigra in Parkinson's disease (PD) coupled to the therapeutic benefits of dopaminergic therapies in patients, simplifies the treatment strategy for this disease. In the context of neurotrophic factors, this distils down to the simple question as to whether a factor exists for these cells that can promote their survival in the face of the degenerative disease process. If such a factor exists, and GDNF seems a strong candidate, then one could anticipate that this treatment would be as effective as L-dopa therapy. However it would not be better than this, nor curative, given the extensive pathology in PD. To date a number of clinical trials have been undertaken in which GDNF has been directly delivered to the PD brain. In addition there have been studies in which neurturin (part of the GDNF family) has also been delivered to the CNS using a viral vector delivery system. These trials have produced mixed results. Importantly though, some patients have shown a sustained clinical response to this treatment which correlates with evidence of increased dopaminergic activity in the brain at the site of delivery using F-dopa PET as well as in a single post-mortem study. The challenge therefore is not whether this approach works, because it self-evidently does in some patients, but rather how we can do this more consistently. The core loss of dopaminergic neurons in the substantia nigra in Parkinson's disease (PD) coupled to the therapeutic benefits of dopaminergic therapies in patients, simplifies the treatment strategy for this disease. In the context of neurotrophic factors, this distils down to the simple question as to whether a factor exists for these cells that can promote their survival in the face of the degenerative disease process. If such a factor exists, and GDNF seems a strong candidate, then one could anticipate that this treatment would be as effective as L-dopa therapy. However it would not be better than this, nor curative, given the extensive pathology in PD. To date a number of clinical trials have been undertaken in which GDNF has been directly delivered to the PD brain. In addition there have been studies in which neurturin (part of the GDNF family) has also been delivered to the CNS using a viral vector delivery system. These trials have produced mixed results. Importantly though, some patients have shown a sustained clinical response to this treatment which correlates with evidence of increased dopaminergic activity in the brain at the site of delivery using F-dopa PET as well as in a single post-mortem study. The challenge therefore is not whether this approach works, because it self-evidently does in some patients, but rather how we can do this more consistently." @default.
• W2023598302 created "2016-06-24" @default.
• W2023598302 creator A5084748006 @default.
• W2023598302 date "2009-12-01" @default.
• W2023598302 modified "2023-09-26" @default.
• W2023598302 title "Parkinson's disease and growth factors – are they the answer?" @default.
• W2023598302 cites W1973587330 @default.
• W2023598302 cites W1976997469 @default.
• W2023598302 cites W1991208841 @default.
• W2023598302 cites W1991214068 @default.
• W2023598302 cites W1996001296 @default.
• W2023598302 cites W1997631088 @default.
• W2023598302 cites W2000560434 @default.
• W2023598302 cites W2008001474 @default.
• W2023598302 cites W2010756280 @default.
• W2023598302 cites W2030549077 @default.
• W2023598302 cites W2045282945 @default.
• W2023598302 cites W2054700826 @default.
• W2023598302 cites W2054810445 @default.
• W2023598302 cites W2059634474 @default.
• W2023598302 cites W2061744249 @default.
• W2023598302 cites W2062048315 @default.
• W2023598302 cites W2072368655 @default.
• W2023598302 cites W2075885094 @default.
• W2023598302 cites W2084543881 @default.
• W2023598302 cites W2085261999 @default.
• W2023598302 cites W2085953070 @default.
• W2023598302 cites W2090673961 @default.
• W2023598302 cites W2095639798 @default.
• W2023598302 cites W2102491127 @default.
• W2023598302 cites W2103899142 @default.
• W2023598302 cites W2108724455 @default.
• W2023598302 cites W2145568285 @default.
• W2023598302 cites W2154452702 @default.
• W2023598302 cites W2156202012 @default.
• W2023598302 cites W2165526364 @default.
• W2023598302 cites W2415863638 @default.
• W2023598302 cites W4250098950 @default.
• W2023598302 doi "https://doi.org/10.1016/s1353-8020(09)70810-7" @default.
• W2023598302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20082986" @default.
• W2023598302 hasPublicationYear "2009" @default.
• W2023598302 type Work @default.
• W2023598302 sameAs 2023598302 @default.
• W2023598302 citedByCount "18" @default.
• W2023598302 countsByYear W20235983022012 @default.
• W2023598302 countsByYear W20235983022013 @default.
• W2023598302 countsByYear W20235983022014 @default.
• W2023598302 countsByYear W20235983022016 @default.
• W2023598302 countsByYear W20235983022017 @default.
• W2023598302 countsByYear W20235983022023 @default.
• W2023598302 crossrefType "journal-article" @default.
• W2023598302 hasAuthorship W2023598302A5084748006 @default.
• W2023598302 hasConcept C126322002 @default.
• W2023598302 hasConcept C137183658 @default.
• W2023598302 hasConcept C151730666 @default.
• W2023598302 hasConcept C15744967 @default.
• W2023598302 hasConcept C160539049 @default.
• W2023598302 hasConcept C169760540 @default.
• W2023598302 hasConcept C170493617 @default.
• W2023598302 hasConcept C185856081 @default.
• W2023598302 hasConcept C2777603835 @default.
• W2023598302 hasConcept C2779134260 @default.
• W2023598302 hasConcept C2779343474 @default.
• W2023598302 hasConcept C2779734285 @default.
• W2023598302 hasConcept C2780938664 @default.
• W2023598302 hasConcept C513476851 @default.
• W2023598302 hasConcept C535046627 @default.
• W2023598302 hasConcept C71924100 @default.
• W2023598302 hasConcept C86803240 @default.
• W2023598302 hasConceptScore W2023598302C126322002 @default.
• W2023598302 hasConceptScore W2023598302C137183658 @default.
• W2023598302 hasConceptScore W2023598302C151730666 @default.
• W2023598302 hasConceptScore W2023598302C15744967 @default.
• W2023598302 hasConceptScore W2023598302C160539049 @default.
• W2023598302 hasConceptScore W2023598302C169760540 @default.
• W2023598302 hasConceptScore W2023598302C170493617 @default.
• W2023598302 hasConceptScore W2023598302C185856081 @default.
• W2023598302 hasConceptScore W2023598302C2777603835 @default.
• W2023598302 hasConceptScore W2023598302C2779134260 @default.
• W2023598302 hasConceptScore W2023598302C2779343474 @default.
• W2023598302 hasConceptScore W2023598302C2779734285 @default.
• W2023598302 hasConceptScore W2023598302C2780938664 @default.
• W2023598302 hasConceptScore W2023598302C513476851 @default.
• W2023598302 hasConceptScore W2023598302C535046627 @default.
• W2023598302 hasConceptScore W2023598302C71924100 @default.
• W2023598302 hasConceptScore W2023598302C86803240 @default.
• W2023598302 hasLocation W20235983021 @default.
• W2023598302 hasLocation W20235983022 @default.
• W2023598302 hasOpenAccess W2023598302 @default.
• W2023598302 hasPrimaryLocation W20235983021 @default.
• W2023598302 hasRelatedWork W1967738091 @default.
• W2023598302 hasRelatedWork W2004116738 @default.
• W2023598302 hasRelatedWork W2014102562 @default.
• W2023598302 hasRelatedWork W2023598302 @default.
• W2023598302 hasRelatedWork W2323121955 @default.
• W2023598302 hasRelatedWork W2346430935 @default.
• W2023598302 hasRelatedWork W3083703281 @default.
• W2023598302 hasRelatedWork W3126639184 @default.

• next